Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Dec;86(4):899–904. doi: 10.1111/j.1476-5381.1985.tb11112.x

Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine.

A G Hayes, M J Sheehan, M B Tyers
PMCID: PMC1916625  PMID: 3000501

Abstract

The irreversible inhibitor of mu-opioid receptor-mediated effects, beta-funaltrexamine (beta-FNA), was used to investigate the selectivity of various opioid agonists at mu-opioid receptors in the electrically stimulated guinea-pig ileum and mouse vas deferens preparations in vitro. In the guinea-pig ileum, pretreatment with beta-FNA (3 X 10(-8) - 3 X 10(-6)M) produced a concentration-dependent antagonism of the inhibitory effect produced by the mu-opioid receptor agonist [D-Ala2, MePhe4, Gly(ol)5]enkephalin (DAGO). High concentrations of beta-FNA (3 X 10(-6) - 1 X 10(-5)M) also antagonized the inhibitory effects of the kappa-opioid agonist U50488. Pretreatment of guinea-pig ileum with beta-FNA at 1 X 10(-6)M resulted in blockade of the effect of some opioid agonists. The compounds which showed the largest rightward shifts in their concentration-response curves, and hence the greatest mu/kappa opioid receptor selectivity, were nalbuphine, [D-Ser2, Leu5]enkephalinyl-Thr6(DSLET), morphine, DAGO and normorphine. Responses to tifluadom, Mr 2034, ethylketocyclazocine, butorphanol, nalorphine, proxorphan and U50488 were not inhibited by beta-FNA. In the mouse vas deferens, pre-treatment with beta-FNA (1 X 10(-6)M) produced a similar shift in the dose-response curves for normorphine as in the guinea-pig ileum. The concentration-response curves for the delta-receptor agonists [D-Ala2, D-Leu5] enkephalin (DADLE) and DSLET were, however, also shifted, indicating that beta-FNA will also block delta-opioid receptors. Since beta-FNA does not block kappa-opioid receptor-mediated effects, it can be used in the guinea-pig ileum preparation as a selective mu-receptor inhibitor. However, its lack of selectivity between mu- and delta-opioid receptors should be taken into account in many other isolated tissues and experiments in vivo.

Full text

PDF
899

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burkard W. P. [3H]Tifluadom binding in guinea-pig brain membranes. Eur J Pharmacol. 1984 Jan 27;97(3-4):337–338. doi: 10.1016/0014-2999(84)90473-4. [DOI] [PubMed] [Google Scholar]
  3. Gacel G., Fournie-Zaluski M. C., Roques B. P. D-Tyr--Ser-Gly--Phe--Leu--Thr, a highly preferential ligand for delta-opiate receptors. FEBS Lett. 1980 Sep 8;118(2):245–247. doi: 10.1016/0014-5793(80)80229-8. [DOI] [PubMed] [Google Scholar]
  4. Gillan M. G., Kosterlitz H. W., Paterson S. J. Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol. 1980 Nov;70(3):481–490. doi: 10.1111/j.1476-5381.1980.tb08727.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hayes A., Kelly A. Profile of activity of kappa receptor agonists in the rabbit vas deferens. Eur J Pharmacol. 1985 Apr 16;110(3):317–322. doi: 10.1016/0014-2999(85)90558-8. [DOI] [PubMed] [Google Scholar]
  6. Hutchinson M., Kosterlitz H. W., Leslie F. M., Waterfield A. A. Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey. Br J Pharmacol. 1975 Dec;55(4):541–546. doi: 10.1111/j.1476-5381.1975.tb07430.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Johnson N., Pasternak G. W. The binding to rat brain homogenates of Mr2034, a universal opiate. Life Sci. 1983 Sep 5;33(10):985–991. doi: 10.1016/0024-3205(83)90755-5. [DOI] [PubMed] [Google Scholar]
  8. Kosterlitz H. W., Leslie F. M. Comparison of the receptor binding characteristics of opiate agonists interacting with mu- or kappa-receptors. Br J Pharmacol. 1978 Dec;64(4):607–614. doi: 10.1111/j.1476-5381.1978.tb17323.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kosterlitz H. W., Lord J. A., Paterson S. J., Waterfield A. A. Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with mu- and delta-receptors. Br J Pharmacol. 1980 Feb;68(2):333–342. doi: 10.1111/j.1476-5381.1980.tb10422.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kosterlitz H. W., Paterson S. J., Robson L. E. Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain. Br J Pharmacol. 1981 Aug;73(4):939–949. doi: 10.1111/j.1476-5381.1981.tb08749.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Leslie F. M., Chavkin C., Cox B. M. Opioid binding properties of brain and peripheral tissues: evidence for heterogeneity in opioid ligand binding sites. J Pharmacol Exp Ther. 1980 Aug;214(2):395–402. [PubMed] [Google Scholar]
  12. Lord J. A., Waterfield A. A., Hughes J., Kosterlitz H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977 Jun 9;267(5611):495–499. doi: 10.1038/267495a0. [DOI] [PubMed] [Google Scholar]
  13. Martin W. R., Eades C. G., Thompson J. A., Huppler R. E., Gilbert P. E. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976 Jun;197(3):517–532. [PubMed] [Google Scholar]
  14. Maurer R. Multiplicity of opiate receptors in different species. Neurosci Lett. 1982 Jun 30;30(3):303–307. doi: 10.1016/0304-3940(82)90417-7. [DOI] [PubMed] [Google Scholar]
  15. McKnight A. T., Paterson S. J., Corbett A. D., Kosterlitz H. W. Acute and persistent effects of beta-funaltrexamine on the binding and agonist potencies of opioids in the myenteric plexus of the guinea-pig ileum. Neuropeptides. 1984 Dec;5(1-3):169–172. doi: 10.1016/0143-4179(84)90054-4. [DOI] [PubMed] [Google Scholar]
  16. Merz H., Stockhaus K. N-[(Tetrahydrofuryl)alkyl] and N-(alkoxyalkyl) derivatives of (-)-normetazocine, compounds with differentiated opioid action profiles. J Med Chem. 1979 Dec;22(12):1475–1483. doi: 10.1021/jm00198a009. [DOI] [PubMed] [Google Scholar]
  17. Portoghese P. S., Larson D. L., Sayre L. M., Fries D. S., Takemori A. E. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem. 1980 Mar;23(3):233–234. doi: 10.1021/jm00177a002. [DOI] [PubMed] [Google Scholar]
  18. Portoghese P. S., Takemori A. E. Different receptor sites mediate opioid agonism and antagonism. J Med Chem. 1983 Oct;26(10):1341–1343. doi: 10.1021/jm00364a001. [DOI] [PubMed] [Google Scholar]
  19. Rothman R. B., Bowen W. D., Schumacher U. K., Pert C. B. Effect of beta-FNA on opiate receptor binding: preliminary evidence for two types of mu receptors. Eur J Pharmacol. 1983 Nov 11;95(1-2):147–148. doi: 10.1016/0014-2999(83)90282-0. [DOI] [PubMed] [Google Scholar]
  20. Römer D., Büscher H. H., Hill R. C., Maurer R., Petcher T. J., Zeugner H., Benson W., Finner E., Milkowski W., Thies P. W. An opioid benzodiazepine. Nature. 1982 Aug 19;298(5876):759–760. doi: 10.1038/298759a0. [DOI] [PubMed] [Google Scholar]
  21. Vonvoigtlander P. F., Lahti R. A., Ludens J. H. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther. 1983 Jan;224(1):7–12. [PubMed] [Google Scholar]
  22. Ward A., Takemori A. E. Studies on the narcotic receptor in the guinea-pig ileum. J Pharmacol Exp Ther. 1976 Oct;199(1):117–123. [PubMed] [Google Scholar]
  23. Ward S. J., Portoghese P. S., Takemori A. E. Improved assays for the assessment of kappa- and delta-properties of opioid ligands. Eur J Pharmacol. 1982 Nov 19;85(2):163–170. doi: 10.1016/0014-2999(82)90461-7. [DOI] [PubMed] [Google Scholar]
  24. Ward S. J., Portoghese P. S., Takemori A. E. Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther. 1982 Mar;220(3):494–498. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES